These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8118284)

  • 41. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H
    Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cervical cancer: Biomarkers for diagnosis and treatment.
    Dasari S; Wudayagiri R; Valluru L
    Clin Chim Acta; 2015 May; 445():7-11. PubMed ID: 25773118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?
    Chan YM; Ng TY; Ngan HY; Wong LC
    Gynecol Oncol; 2002 Jan; 84(1):7-11. PubMed ID: 11748969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome.
    Scambia G; Benedetti Panici ; Foti E; Ferrandina G; Leone FP; Marciano M; Mancuso S
    Eur J Cancer; 1996 Feb; 32A(2):259-63. PubMed ID: 8664038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients.
    Li J; Cheng H; Zhang P; Dong Z; Tong HL; Han JD; Guo F; Tian YP
    Clin Chim Acta; 2013 Sep; 424():292-7. PubMed ID: 23850705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
    Abe A; Nakano T; Morita S; Oka K
    Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A; Tana R; Fanucchi A; Genazzani AR
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
    Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix.
    Ikeda S; Yoshimura K; Onda T; Kasamatsu T; Kato T; Ishikawa M; Sasajima Y; Tsuda H
    J Obstet Gynaecol Res; 2012 Oct; 38(10):1260-5. PubMed ID: 22563932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study.
    Niibe Y; Kazumoto T; Toita T; Yamazaki H; Higuchi K; Ii N; Suzuki K; Uno T; Tokumaru S; Takayama M; Sekiguchi K; Matsumoto Y; Michimoto K; Oguchi M; Hayakawa K
    Gynecol Oncol; 2006 Nov; 103(2):435-8. PubMed ID: 16677691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer.
    Micke O; Prott FJ; Schäfer U; Tangerding S; Pötter R; Willich N
    Anticancer Res; 2000; 20(6D):5113-5. PubMed ID: 11326679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer.
    Mabuchi S; Matsumoto Y; Hamasaki T; Kawano M; Hisamatsu T; Mutch DG; Kimura T
    Int J Gynecol Cancer; 2012 Nov; 22(9):1545-51. PubMed ID: 23051956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
    Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
    Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Determination of the SCC antigen in the serum of patients with cervical cancer].
    Crombach G; Würz H; Bolte A
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):439-45. PubMed ID: 3623046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
    Hirakawa M; Nagai Y; Inamine M; Kamiyama K; Ogawa K; Toita T; Murayama S; Aoki Y
    Gynecol Oncol; 2008 Jan; 108(1):126-9. PubMed ID: 17936344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix.
    Ohno T; Nakayama Y; Nakamoto S; Kato S; Imai R; Nonaka T; Ishikawa H; Harashima K; Suzuki Y
    Cancer; 2003 Jun; 97(12):3114-20. PubMed ID: 12784349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.